The prognostic benefit from intermediate-dose cytarabine as consolidation therapy varies by cytogenetic subtype in t(8;21) acute myeloid leukemia: a retrospective cohort study

BACKGROUND: Patients with different karyotypes had different prognosis in t(8;21) acute myeloid leukemia (AML). Cytarabine (Ara-C) plays an important role as consolidation therapy in t(8;21) AML. T(8;21) AML patients with different karyotypes responded differently to post-remission therapy with Ara-...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Guofeng, Yang, Jiaqi, Cao, Fuliang, Zhou, Wei, Gong, Dan, Liu, Liren, Zhou, Dejun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469173/
https://www.ncbi.nlm.nih.gov/pubmed/36111020
http://dx.doi.org/10.21037/atm-22-2965

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469173/
https://www.ncbi.nlm.nih.gov/pubmed/36111020
http://dx.doi.org/10.21037/atm-22-2965

Ejemplares similares